Immunovant (IMVT)
(Delayed Data from NSDQ)
$30.40 USD
+0.47 (1.57%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $30.38 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$30.40 USD
+0.47 (1.57%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $30.38 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Zacks News
Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
by Zacks Equity Research
Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Immunovant, Inc. (IMVT) Up 6.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.
Immunovant, Inc. (IMVT) Down 12.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
Immunovant (IMVT) Gains on a Potential Buyout by Roivant
by Zacks Equity Research
Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?
by Zacks Equity Research
Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.
Should You Buy Immunovant (IMVT) Ahead of Earnings?
by Zacks Equity Research
Immunovant (IMVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.
Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.
Immunovant (IMVT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Immunovant (IMVT) has been struggling lately, but the selling pressure may be coming to an end soon.
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
by Zacks Equity Research
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.
Coupa Software (COUP) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Coupa Software's (COUP) third-quarter fiscal 2021 results benefit from continued strength in adoption of the company's solutions including Business Spend Management and Coupa Pay.
Reata (RETA) Omaveloxolone Program Faces Delay on FDA Update
by Zacks Equity Research
Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.
Immunovant Up on Positive Data From Myasthenia Gravis Study
by Zacks Equity Research
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
Company News for Aug 26, 2020
by Zacks Equity Research
Companies in the news are: MDT, SJM, AAL, IMVT